{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-042498","form_type":"8-K","ticker":null,"cik":"0001556263","company_name":"Syros Pharmaceuticals, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.982872+00:00","generated_at":"2026-05-25T23:02:43.273795+00:00","sec_items":["3.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Syros Pharmaceuticals to voluntarily delist from Nasdaq; CEO Quirk steps down, wind-down underway","bullets":["Voluntary delisting from Nasdaq; Form 25 to be filed ~March 10, 2025, effective ~March 20; intends to file Form 15 to suspend SEC reporting.","CEO Gerald Quirk steps down as CEO/President effective March 1; remains on Board as director and consultant.","Directors Peter Wirth, Marsha Fanucci, Nancy Simonian resign from Board effective immediately; no disagreement.","Matthew Foster appointed Chief Restructuring Officer effective March 1 to oversee wind-down.","Wind-down triggered by Phase 3 trial (SELECT-MDS-1) failure and default under Oxford Finance loan; operating under Oxford-approved budget."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-042498","json":"https://secwatch.observer/filing/0001193125-25-042498.json","markdown":"https://secwatch.observer/filing/0001193125-25-042498.md","text":"https://secwatch.observer/filing/0001193125-25-042498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/d926755d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:02:43.273795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06dc6e3a5c","claim":"Gerald Quirk departed as Chief Executive Officer and President at Syros Pharmaceuticals, Inc..","evidence_excerpt":"Effective March 1, 2025, Gerald Quirk will cease to serve as Chief Executive Officer and President of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease to serve"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"},{"claim_id":"09a84aea96","claim":"Marsha H. Fanucci resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0bd180a1e3","claim":"Nancy Simonian resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5fb5526253","claim":"Peter Wirth resigned as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e528c89c7","claim":"Gerald Quirk was appointed as Director at Syros Pharmaceuticals, Inc..","evidence_excerpt":"On February 28, 2025, Gerald Quirk was appointed to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}